With vaccine revenue crumbling and layoffs in full swing, is Moderna’s slimmed-down strategy a smart move or a red flag for ...

Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the ...

Termination of contracts and “de-scoping” of mRNA-related work in existing contracts, along with other changes, will affect ...

Q2 2025 Earnings Call Transcript August 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.13, ...

When COVID-19 cases were surging, Dr. David Wohl saw patients “hungry for air” fill UNC hospital wards. What most saved lives ...

RFK Jr. recently made major cuts to mRNA vaccine development research, questioning their safety. Should you still get the ...

Messenger RNA vaccines, or mRNA, differ from traditional ones. Instead of growing a virus and weakening it to allow the body to engage its natural defenses, mRNA vaccines use pieces of genetic code to ...

In a report released yesterday, Cory Kasimov from Evercore ISI maintained a Hold rating on Moderna, with a price target of $32.00. The company’s shares closed yesterday at $27.64. Take advantage of ...

This was one in a continuing line of moves that have put Kennedy's vaccine skepticism into public policy, though scientists ...

In justifying the government's termination of $500 million in funding for mRNA vaccine projects, Health and Human Services ...

Pfizer (PFE), and Sanofi (SNY) drew increased attention on Tuesday as traders reacted to the U.S. government’s move to halt ...

Neither UTMB nor Moderna has confirmed the nature of the project included in the announcement, or how much funding is being ...